Access the full text.
Sign up today, get DeepDyve free for 14 days.
Haijiao Zhang, A. Paliga, Evie Hobbs, S. Moore, S. Olson, Nicola Long, K. Dao, J. Tyner (2018)
Two myeloid leukemia cases with rare FLT3 fusionsCold Spring Harbor Molecular Case Studies, 4
F. Roufosse, J. Kahn, M. Rothenberg, A. Wardlaw, A. Klion, S. Kirby, M. Gilson, J. Bentley, E. Bradford, S. Yancey, J. Steinfeld, G. Gleich (2020)
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trialThe Journal of allergy and clinical immunology, 146
W. Xie, Sa Wang, Shimin Hu, Jie Xu, L. Medeiros, G. Tang (2018)
Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.Cancer genetics, 228-229
G. Metzgeroth, J. Schwaab, D. Gosenca, A. Fabarius, C. Haferlach, A. Hochhaus, N. Cross, N. Cross, W. Hofmann, A. Reiter (2013)
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phaseLeukemia, 27
B. Bain, Shahzaib Ahmad (2014)
Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities?British Journal of Haematology, 166
E. Rumi, J. Milosevic, I. Casetti, Irene Dambruoso, D. Pietra, E. Boveri, M. Boni, P. Bernasconi, F. Passamonti, R. Kralovics, M. Cazzola (2013)
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 17
R. King, Brent Tan, F. Craig, T. George, H. Horny, K. Kelemen, A. Orazi, K. Reichard, L. Rimsza, Sa Wang, A. Zamó, L. Quintanilla‐Martinez (2020)
Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome.American journal of clinical pathology
I. Alvarez-Twose, M. Jara-Acevedo, J. Morgado, A. García-Montero, L. Sánchez-Muñoz, Cristina Teodosio, A. Matito, A. Mayado, C. Caldas, M. Mollejo, A. Órfão, L. Escribano (2016)
Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.The Journal of allergy and clinical immunology, 137 1
(2018)
Recurrent activating STAT 5 B N 642 H mutation in myeloid neoplasms 1 with eosinophilia
M. Jawhar, N. Naumann, M. Knut, J. Score, Muna Ghazzawi, Brigitte Schneider, K. Kreuzer, M. Hallek, H. Drexler, J. Chacko, L. Wallis, A. Fabarius, G. Metzgeroth, W. Hofmann, A. Chase, W. Tapper, A. Reiter, N. Cross (2017)
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophiliaLeukemia, 31
A. Reiter, C. Walz, A. Watmore, C. Schoch, I. Blau, B. Schlegelberger, U. Berger, N. Telford, S. Aruliah, J. Yin, D. Vanstraelen, H. Barker, P. Taylor, A. O'Driscoll, F. Benedetti, C. Rudolph, H. Kolb, A. Hochhaus, R. Hehlmann, A. Chase, N. Cross (2005)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.Cancer research, 65 7
C. Baer, Verena Muehlbacher, W. Kern, C. Haferlach, T. Haferlach (2018)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2Haematologica, 103
S. Qu, T. Qin, Ze-feng Xu, Yue Zhang, X. Ai, Bing Li, Hong-li Zhang, L. Fang, L. Pan, N. Hu, Z. Xiao (2016)
Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in ChinaOncotarget, 7
J. Craig, R. Hasserjian, Annette Kim, Annette Kim, J. Aster, J. Aster, G. Pinkus, G. Pinkus, J. Hornick, J. Hornick, D. Steensma, R. Lindsley, D. DeAngelo, E. Morgan, E. Morgan (2020)
Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosisModern Pathology
R. Million, N. Harakawa, S. Roumiantsev, L. Varticovski, R. Etten (2004)
A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine KinaseMolecular and Cellular Biology, 24
T. Tran, M. Harris, Jonathan Nguyen, Traci Blonquist, K. Stevenson, Eileen Stonerock, B. Asselin, U. Athale, L. Clavell, P. Cole, K. Kelly, C. Laverdière, J. Leclerc, B. Michon, M. Schorin, J. Welch, S. Reshmi, D. Neuberg, S. Sallan, M. Loh, L. Silverman (2018)
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.Blood advances, 2 5
J. Gotlib, J. Kiladjian, A. Vannucchi, A. Rambaldi, A. Reiter, William Shomali, T. George, Jay Patel, Philomena Colucci, C. Walker, H. Zhen, S. Verstovsek (2021)
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)Blood
Óscar González-López, J. Muñoz-González, A. Órfão, I. Alvarez-Twose, A. García-Montero (2022)
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic MastocytosisCancers, 14
D. DeAngelo, D. Radia, T. George, W. Robinson, A. Quiery, M. Drummond, P. Bose, E. Hexner, E. Winton, H. Horny, M. Tugnait, O. Schmidt-Kittler, E. Evans, Hui-Min Lin, B. Mar, S. Verstovsek, M. Deininger, J. Gotlib (2021)
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialNature Medicine, 27
Niloufar Hosseini, K. Craddock, S. Salehi-rad, S. Brennan, D. Bailey, J. Brandwein, A. Porwit (2014)
ETV6/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophiliaJournal of Hematopathology, 7
N. Telford, Seema Alexander, Owen McGinn, M. Williams, K. Wood, A. Bloor, V. Saha (2016)
Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6–LYN gene fusionBlood Cancer Journal, 6
Paula Navarro-Navarro, I. Alvarez-Twose, A. Pérez-Pons, Ana Henriques, A. Mayado, A. García-Montero, L. Sánchez-Muñoz, Óscar González-López, A. Matito, C. Caldas, M. Jara-Acevedo, A. Órfão (2022)
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromesAllergy, 78
G. Hoermann, Karoline Gleixner, Graziella Dinu, Michael Kundi, Georg Greiner, F. Wimazal, E. Hadzijusufovic, E. Hadzijusufovic, G. Mitterbauer, Christine Mannhalter, Peter Valent, W. Sperr (2014)
The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the diseaseAllergy, 69
F. Vega, L. Medeiros, Rajayogesh Davuluri, Candy Cromwell, S. Alkan, L. Abruzzo (2008)
t(8;13)-positive Bilineal Lymphomas: Report of 6 CasesThe American Journal of Surgical Pathology, 32
Ken-Hong Lim, A. Tefferi, T. Lasho, C. Finke, M. Patnaik, J. Butterfield, R. Mcclure, chin-Yang Li, A. Pardanani (2009)
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.Blood, 113 23
(2020)
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2Definitions
Johannes Lübke, J. Schwaab, N. Naumann, H. Horny, C. Weiss, G. Metzgeroth, S. Kreil, N. Cross, K. Sotlar, A. Fabarius, W. Hofmann, P. Valent, J. Gotlib, M. Jawhar, A. Reiter (2022)
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based AnalysisJournal of Clinical Oncology, 40
Nana Matsumoto, Ji Yuan, Jun Wang, Q. Shen, X. Chen, Young Kim, C. Zuppan, C. Chang, W. Cui, Dong Chen, M. Shi, Savanah Gisriel, Mingyi Chen, Mina Xu, Zenggang Pan (2022)
Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literatureModern Pathology, 35
A. Pardanani, A. Tefferi (2010)
Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literatureCurrent Opinion in Hematology, 17
A. Pardanani, T. Lasho, Y. Elala, E. Wassie, C. Finke, K. Reichard, Dong Chen, C. Hanson, R. Ketterling, A. Tefferi (2016)
Next‐generation sequencing in systemic mastocytosis: Derivation of a mutation‐augmented clinical prognostic model for survivalAmerican Journal of Hematology, 91
Jennifer Poitras, P. Cin, J. Aster, D. DeAngelo, C. Morton (2008)
Novel SSBP2‐JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemiaGenes, 47
A. Pardanani, T. Lasho, E. Wassie, C. Finke, D. Zblewski, C. Hanson, R. Ketterling, N. Gangat, A. Tefferi (2016)
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencingLeukemia, 30
J. Morgado, O. Perbellini, Ryan Johnson, Cristina Teodosio, A. Matito, I. Alvarez-Twose, P. Bonadonna, A. Zamó, M. Jara-Acevedo, A. Mayado, A. García-Montero, M. Mollejo, T. George, R. Zanotti, A. Órfão, L. Escribano, L. Sánchez-Muñoz (2013)
CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosisHistopathology, 63
A. Pardanani (2018)
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 94
V. Najfeld, A. Cozza, Windy Berkofsy-Fessler, J. Prchal, A. Scalise (2007)
Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.Experimental hematology, 35 11
J. Muñoz-González, M. Jara-Acevedo, I. Alvarez-Twose, J. Merker, Cristina Teodosio, Yanli Hou, Ana Henriques, Krishna Roskin, L. Sánchez-Muñoz, Albert Tsai, C. Caldas, A. Matito, J. Sánchez-Gallego, A. Mayado, Noelia Dasilva-Freire, J. Gotlib, L. Escribano, A. Órfão, A. García-Montero (2018)
Impact of somatic and germline mutations on the outcome of systemic mastocytosis.Blood advances, 2 21
Sa Wang, R. Hasserjian, W. Tam, Albert Tsai, J. Geyer, T. George, K. Foucar, H. Rogers, E. Hsi, Bryan Rea, A. Bagg, C. Bueso-Ramos, D. Arber, S. Verstovsek, A. Orazi (2017)
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndromeHaematologica, 102
I. Alvarez-Twose, D. Olano, L. Sánchez-Muñoz, A. Matito, María Esteban-López, A. Vega, Maria Mateo, M. Durana, B. Hoz, M. Gil, T. Caballero, A. Rosado, Isabel Matas, Cristina Teodosio, M. Jara-Acevedo, M. Mollejo, A. García-Montero, A. Órfão, L. Escribano (2010)
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.The Journal of allergy and clinical immunology, 125 6
S. Tasian, M. Loh, S. Hunger (2017)
Philadelphia chromosome-like acute lymphoblastic leukemia.Blood, 130 19
N. Naumann, M. Jawhar, J. Schwaab, Sebastian Kluger, Johannes Lübke, G. Metzgeroth, H. Popp, Nada Khaled, H. Horny, K. Sotlar, P. Valent, C. Haferlach, G. Göhring, B. Schlegelberger, M. Meggendorfer, W. Hofmann, N. Cross, A. Reiter, A. Fabarius (2018)
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosisGenes, 57
P. Valent, K. Sotlar, W. Sperr, L. Escribano, S. Yavuz, A. Reiter, T. George, H. Kluin-Nelemans, O. Hermine, J. Butterfield, H. Hägglund, C. Ustun, J. Hornick, M. Triggiani, D. Radia, C. Akin, K. Hartmann, J. Gotlib, L. Schwartz, S. Verstovsek, A. Órfão, D. Metcalfe, M. Arock, H. Horny (2014)
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.Annals of oncology : official journal of the European Society for Medical Oncology, 25 9
M. Kasbekar, V. Nardi, P. Cin, A. Brunner, M. Burke, Yi-Bin Chen, Christine Connolly, A. Fathi, Julia Foster, M. Macrae, S. Mcafee, K. McGregor, Rupa Narayan, Aura Ramos, Tina Som, M. Vartanian, Robb Friedman, K. Benhadji, G. Hobbs (2020)
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.Blood advances, 4 13
J. Schwaab, M. Knut, C. Haferlach, G. Metzgeroth, H. Horny, A. Chase, W. Tapper, J. Score, K. Waghorn, N. Naumann, M. Jawhar, A. Fabarius, W. Hofmann, N. Cross, A. Reiter (2015)
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesAnnals of Hematology, 94
J. Schwaab, N. Naumann, Johannes Luebke, M. Jawhar, T. Somervaille, Mark Williams, R. Frewin, P. Jost, F. Lichtenegger, P. Rosée, N. Storch, T. Haferlach, H. Horny, A. Fabarius, C. Haferlach, A. Burchert, W. Hofmann, N. Cross, A. Hochhaus, A. Reiter, G. Metzgeroth (2020)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genesAmerican Journal of Hematology, 95
N. Butt, J. Lambert, Sahra Ali, P. Beer, N. Cross, A. Duncombe, J. Ewing, C. Harrison, S. Knapper, D. Mclornan, A. Mead, D. Radia, B. Bain (2017)
Guideline for the investigation and management of eosinophiliaBritish Journal of Haematology, 176
L. Falchi, M. Mehrotra, K. Newberry, L. Lyle, G. Lu, K. Patel, R. Luthra, U. Popat, S. Verstovsek (2014)
ETV6–FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplantLeukemia, 28
Meiyu Chen, Kai Wang, X. Cai, Xiuwen Zhang, H. Chao, Suning Chen, Hongjie Shen, Qian Wang, Ri Zhang (2021)
Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosisHematology, 26
Hong Fang, G. Tang, S. Loghavi, P. Greipp, Wei Wang, S. Verstovsek, L. Medeiros, K. Reichard, R. Miranda, Sa Wang (2020)
Systematic use of fluorescence in‐situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasmsHistopathology, 76
F. Jendoubi, N. Gaudenzio, A. Gallini, M. Negretto, C. Paul, C. Livideanu (2020)
Omalizumab in the treatment of adult patients with mastocytosis: A systematic reviewClinical & Experimental Allergy, 50
P. Valent, C. Akin, K. Hartmann, I. Alvarez-Twose, K. Brockow, O. Hermine, M. Niedoszytko, J. Schwaab, J. Lyons, M. Carter, H. Elberink, J. Butterfield, T. George, Georg Greiner, C. Ustun, P. Bonadonna, K. Sotlar, G. Nilsson, M. Jawhar, F. Siebenhaar, S. Broesby‐Olsen, S. Yavuz, R. Zanotti, M. Lange, B. Nedoszytko, G. Hoermann, M. Castells, D. Radia, J. Muñoz-González, W. Sperr, M. Triggiani, H. Kluin-Nelemans, S. Galli, L. Schwartz, A. Reiter, A. Órfão, J. Gotlib, M. Arock, H. Horny, D. Metcalfe (2021)
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus ProposalHemaSphere, 5
D. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. Borowitz, M. Beau, C. Bloomfield, M. Cazzola, J. Vardiman (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood, 127 20
BJ Bain, H‐P Horny, DA Arber, A Tefferi, RP Hasserjian (2017)
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangements of PDGFRA, PDGFRB or FGFR1, or with PCM1‐JAK2, in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
E. Rumi, J. Milosevic, D. Selleslag, I. Casetti, E. Lierman, D. Pietra, C. Cavalloni, M. Bellini, C. Milanesi, Irene Dambruoso, C. Astori, R. Kralovics, P. Vandenberghe, M. Cazzola (2015)
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion geneAnnals of Hematology, 94
G Russano de Paiva Silva, E Tournier, LO Sarian (2018)
Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study, 97
Laura Brown, Da Zhang, D. Persons, A. Yacoub, S. Ponnala, W. Cui (2016)
A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33)Case Reports in Hematology, 2016
J. Gotlib, A. Reiter, D. Radia, M. Deininger, T. George, J. Panse, A. Vannucchi, U. Platzbecker, I. Alvarez-Twose, A. Mital, O. Hermine, I. Dybedal, E. Hexner, L. Hicks, L. Span, R. Mesa, P. Bose, K. Pettit, M. Heaney, S. Oh, J. Sen, Hui-Min Lin, B. Mar, D. DeAngelo (2021)
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialNature Medicine, 27
C. Akin, G. Fumo, A. Yavuz, P. Lipsky, L. Neckers, D. Metcalfe (2004)
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.Blood, 103 8
Daniel DeAngelo, V. Pullarkat, M. Piris-Villaespesa, T. George, Jay Patel, C. Ustun, P. Bose, M. Heaney, J. Sachs, Lei Sun, A. Pilla, B. Exter, H. Jolin, T. Tashi (2022)
Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)Blood
A. Reiter, J. Gotlib, I. Alvarez-Twose, D. Radia, Johannes Lübke, P. Bobbili, Aolin Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. Galinsky, C. Perkins, W. Sperr, P. Sriskandarajah, A. Chin, S. Sendhil, M. Duh, P. Valent, D. DeAngelo (2022)
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisLeukemia, 36
J. Gotlib, J. Schwaab, William Shomali, T. George, D. Radia, M. Castells, M. Carter, K. Hartmann, I. Alvarez-Twose, K. Brockow, P. Bonadonna, O. Hermine, M. Niedoszytko, G. Hoermann, W. Sperr, H. Elberink, F. Siebenhaar, J. Butterfield, C. Ustun, R. Zanotti, M. Triggiani, L. Schwartz, J. Lyons, A. Órfão, K. Sotlar, H. Horny, M. Arock, D. Metcalfe, C. Akin, Johannes Lübke, P. Valent, A. Reiter (2022)
Proposed ECNM-AIM Response Criteria in Advanced Systemic Mastocytosis.The journal of allergy and clinical immunology. In practice
Sahrish Shah, A. Pardanani, Y. Elala, T. Lasho, M. Patnaik, K. Reichard, C. Hanson, R. Ketterling, A. Tefferi (2018)
Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory‐specific incidence and prognostic impact among 348 informative casesAmerican Journal of Hematology, 93
E. Evans, A. Gardino, Joseph Kim, Brian Hodous, A. Shutes, Alison Davis, Xing Zhu, O. Schmidt-Kittler, Douglas Wilson, Kevin Wilson, L. DiPietro, Yulian Zhang, N. Brooijmans, T. LaBranche, A. Wozniak, Y. Gebreyohannes, P. Schöffski, M. Heinrich, D. DeAngelo, Stephen Miller, B. Wolf, N. Kohl, T. Guzi, N. Lydon, A. Boral, C. Lengauer (2017)
A precision therapy against cancers driven by KIT/PDGFRA mutationsScience Translational Medicine, 9
Jinjuan Yao, Lianrong Xu, U. Aypar, H. Meyerson, Dory Londono, Qi Gao, Jeeyeon Baik, James Dietz, R. Benayed, Allison Sigler, M. Yabe, A. Dogan, M. Arcila, M. Roshal, Yanming Zhang, M. Mauro, Wenbin Xiao (2020)
Myeloid/lymphoid neoplasms with eosinophilia/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibitionHaematologica, 106
Jee-Soo Lee, H. Seo, Kyongok Im, S. Park, Sung-Min Kim, E. Lee, Jung-ah Kim, Joon-hee Lee, Sunghoon Kwon, Miyoung Kim, I. Koh, Seungwoo Hwang, Heung-Woo Park, Hye‐Ryun Kang, Kyoung Park, Ju Kim, D. Lee (2017)
Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencingPLoS ONE, 12
P. Akuthota, P. Weller (2015)
Spectrum of Eosinophilic End-Organ Manifestations.Immunology and allergy clinics of North America, 35 3
F. Perna, O. Abdel-Wahab, R. Levine, S. Jhanwar, K. Imada, S. Nimer (2011)
ETV6-ABL1-positive “chronic myeloid leukemia”: clinical and molecular response to tyrosine kinase inhibitionHaematologica, 96
P. Bonadonna, D. González-de-Olano, R. Zanotti, A. Riccio, L. Ferrari, C. Lombardo, A. Rogkakou, L. Escribano, I. Alvarez-Twose, A. Matito, A. Vega, G. Passalacqua (2013)
Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.The journal of allergy and clinical immunology. In practice, 1 5
L. Golkar, J. Bernhard (1997)
MastocytosisThe Lancet, 349
Vanessa Kennedy, C. Perkins, A. Reiter, M. Jawhar, Johannes Lübke, H. Kluin-Nelemans, William Shomali, Cheryl Langford, Justin Abuel, O. Hermine, M. Niedoszytko, A. Górska, A. Mital, P. Bonadonna, R. Zanotti, I. Tanasi, M. Mattsson, H. Hagglund, M. Triggiani, A. Yavuz, J. Panse, D. Christen, M. Heizmann, K. Shoumariyeh, S. Müller, C. Elena, L. Malcovati, Nicolas Fiorelli, Friederike Wortmann, V. Vučinić, K. Brockow, Christos Fokoloros, S. Papageorgiou, C. Breynaert, D. Bullens, M. Doubek, Anja Ilerhaus, I. Angelova-Fischer, O. Solomianyi, J. Várkonyi, V. Sabato, A. Rüfer, T. Schug, M. Hermans, A. Fortina, F. Caroppo, H. Bumbea, Theo Gulen, K. Hartmann, H. Elberink, J. Schwaab, M. Arock, P. Valent, W. Sperr, J. Gotlib (2022)
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM RegistryBlood Advances, 7
G. Lefèvre, M. Copin, C. Roumier, H. Aubert, M. Avenel‐Audran, N. Grardel, S. Poulain, D. Staumont-Sallé, J. Seneschal, G. Salles, K. Ghomari, L. Terriou, C. Leclech, C. Morati-Hafsaoui, F. Morschhauser, O. Lambotte, Félix Ackerman, J. Trauet, S. Geffroy, F. Dumézy, M. Capron, C. Roche-Lestienne, A. Taieb, P. Hatron, S. Dubucquoi, E. Hachulla, L. Prin, M. Labalette, D. Launay, C. Preudhomme, J. Kahn (2015)
CD3−CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorderHaematologica, 100
K. Chonabayashi, M. Hishizawa, M. Matsui, T. Kondo, T. Ohno, T. Ishikawa, A. Takaori-Kondo (2014)
Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophiliaAnnals of Hematology, 93
Michel D, G. Hoermann, K. Sotlar, O. Hermine, W. Sperr, K. Hartmann, K. Brockow, C. Akin, M. Triggiani, S. Broesby‐Olsen, A. Reiter, J. Gotlib, H. Horny, A. Órfão, D. Metcalfe, P. Valent (2022)
Clinical Impact and Proposed Application of Molecular Markers, Genetic Variants and Cytogenetic Analysis in Mast Cell Neoplasms: Status 2022.The Journal of allergy and clinical immunology
P. Valent, Lina Degenfeld-Schonburg, I. Sadovnik, H. Horny, M. Arock, H. Simon, A. Reiter, B. Bochner (2021)
Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexitySeminars in Immunopathology, 43
O. Pozdnyakova, A. Orazi, K. Kelemen, R. King, K. Reichard, F. Craig, L. Quintanilla‐Martinez, L. Rimsza, T. George, H. Horny, Sa Wang (2020)
Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.American journal of clinical pathology
K. Roberts, S. Reshmi, R. Harvey, I. Chen, Kinnari Patel, Eileen Stonerock, H. Jenkins, Yunfeng Dai, M. Valentine, Zhaohui Gu, Yaqi Zhao, Jinghui Zhang, D. Payne‐Turner, M. Devidas, N. Heerema, A. Carroll, E. Raetz, M. Borowitz, B. Wood, L. Mattano, K. Maloney, W. Carroll, M. Loh, C. Willman, J. Gastier-Foster, C. Mullighan, S. Hunger (2018)
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.Blood, 132 8
Lan-shan Huang, Sa Wang, S. Konoplev, C. Bueso-Ramos, B. Thakral, R. Miranda, E. Jabbour, L. Medeiros, R. Kanagal-Shamanna (2016)
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalitiesMedicine, 95
J. Khoury, E. Solary, O. Abla, Yassmine Akkari, R. Alaggio, J. Apperley, R. Bejar, E. Berti, L. Busque, J. Chan, Weina Chen, Xinfa Chen, W. Chng, J. Choi, I. Colmenero, S. Coupland, N. Cross, D. Jong, M. Elghetany, Emiko Takahashi, J. Emile, J. Ferry, L. Fogelstrand, M. Fontenay, U. Germing, S. Gujral, T. Haferlach, C. Harrison, Jennelle Hodge, Shimin Hu, J. Jansen, R. Kanagal-Shamanna, H. Kantarjian, C. Kratz, Xiao-Qiu Li, M. Lim, K. Loeb, S. Loghavi, Andrea Marcogliese, S. Meshinchi, P. Michaels, K. Naresh, Y. Natkunam, R. Nejati, G. Ott, E. Padron, K. Patel, N. Patkar, J. Picarsic, U. Platzbecker, Irene Roberts, Anna Schuh, W. Sewell, R. Siebert, P. Tembhare, J. Tyner, S. Verstovsek, Wei Wang, Brent Wood, W. Xiao, Cecilia Yeung, A. Hochhaus (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 36
G. Helbig, S. Kyrcz‐Krzemień (2014)
Idiopathic, asymptomatic, and durable blood hypereosinophilia-still many unknowns.The Journal of allergy and clinical immunology, 133 3
A. Pardanani, Ken-Hong Lim, T. Lasho, C. Finke, R. Mcclure, chin-Yang Li, A. Tefferi (2009)
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.Blood, 114 18
William Shomali, J. Gotlib (2021)
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 97
M. Rapanotti, R. Caruso, E. Ammatuna, S. Zaza, L. Trotta, M. Divona, L. Cicconi, D. Funaro, G. Federici, S. Amadori, G. Rossi, F. Lo‐Coco (2010)
Molecular characterization of paediatric idiopathic hypereosinophiliaBritish Journal of Haematology, 151
G. Metzgeroth, J. Schwaab, N. Naumann, M. Jawhar, T. Haferlach, A. Fabarius, A. Hochhaus, W. Hofmann, N. Cross, A. Reiter (2020)
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.Blood advances, 4 3
C. Ustun, J. Gotlib, U. Popat, A. Artz, M. Litzow, A. Reiter, R. Nakamura, H. Kluin-Nelemans, S. Verstovsek, James Gajewski, M. Perales, T. George, T. Shore, W. Sperr, W. Saber, V. Kota, A. Yavuz, V. Pullarkat, J. Rogosheske, W. Hogan, K. Besien, H. Hagglund, G. Damaj, M. Arock, H. Horny, D. Metcalfe, H. Deeg, S. Devine, D. Weisdorf, C. Akin, P. Valent (2016)
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 22 8
K. Roberts, Yongjin Li, D. Payne‐Turner, R. Harvey, Yung‐Li Yang, Deqing Pei, K. McCastlain, L. Ding, Charles Lu, G. Song, Jing Ma, J. Becksfort, Michael Rusch, Shann-Ching Chen, J. Easton, Jinjun Cheng, Kristy Boggs, Natalia Santiago-Morales, I. Iacobucci, R. Fulton, Ji-Rong Wen, M. Valentine, Cheng Cheng, S. Paugh, M. Devidas, I. Chen, S. Reshmi, Amy Smith, Erin Hedlund, P. Gupta, Panduka Nagahawatte, Gang Wu, Xiang Chen, D. Yergeau, Bhavin Vadodaria, H. Mulder, N. Winick, E. Larsen, W. Carroll, N. Heerema, A. Carroll, G. Grayson, S. Tasian, A. Moore, F. Keller, Melissa Frei-Jones, J. Whitlock, E. Raetz, D. White, T. Hughes, Jaime Auvil, Malcolm Smith, G. Marcucci, C. Bloomfield, K. Mrózek, J. Kohlschmidt, W. Stock, S. Kornblau, M. Konopleva, E. Paietta, C. Pui, S. Jeha, M. Relling, W. Evans, D. Gerhard, J. Gastier-Foster, E. Mardis, R. Wilson, M. Loh, J. Downing, S. Hunger, C. Willman, Jinghui Zhang, C. Mullighan (2014)
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.The New England journal of medicine, 371 11
R. Zanotti, M. Bonifacio, Cecilia Isolan, I. Tanasi, L. Crosera, Francesco Olivieri, G. Orsolini, D. Schena, P. Bonadonna (2021)
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM NetworkCancers, 13
G. Damaj, M. Joris, O. Chandesris, K. Hanssens, E. Soucie, D. Canioni, B. Kolb, I. Durieu, E. Gyan, C. Livideanu, S. Cheze, M. Diouf, R. Garidi, S. Georgin-lavialle, V. Asnafi, L. Lhermitte, C. Lavigne, D. Launay, M. Arock, O. Lortholary, P. Dubreuil, O. Hermine (2014)
ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell DiseasesPLoS ONE, 9
A. Tzankov, Karl Sotlar, D. Muhlematter, Alexandre Theocharides, Philip Went, Martine Jotterand, H. Horny, Stephan Dirnhofer (2008)
Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3Journal of Clinical Pathology, 61
E. Braekeleer, N. Douet-Guilbert, D. Rowe, N. Bown, F. Morel, C. Berthou, C. Férec, M. Braekeleer (2011)
ABL1 fusion genes in hematological malignancies: a reviewEuropean Journal of Haematology, 86
G. Helbig, A. Klion (2021)
Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.Blood reviews
K. Reichard, Dong Chen, A. Pardanani, R. Mcclure, M. Howard, Paul Kurtin, A. Wood, R. Ketterling, R. King, R. He, W. Morice, C. Hanson (2015)
Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.American journal of clinical pathology, 144 3
P. Valent, A. Klion, F. Roufosse, D. Simon, G. Metzgeroth, K. Leiferman, J. Schwaab, J. Butterfield, W. Sperr, K. Sotlar, P. Vandenberghe, G. Hoermann, T. Haferlach, R. Moriggl, T. George, C. Akin, B. Bochner, J. Gotlib, A. Reiter, H. Horny, M. Arock, H. Simon, G. Gleich (2022)
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromesAllergy, 78
M. Žaliová, A. Moorman, G. Cazzaniga, M. Stanulla, R. Harvey, K. Roberts, Sue Heatley, M. Loh, M. Konopleva, I. Chen, O. Zimmermannova, C. Schwab, O. Smith, M. Mozziconacci, C. Chabannon, Myungshin Kim, J. Falkenburg, A. Norton, Karen Marshall, Oskar Haas, J. Starkova, J. Stuchly, S. Hunger, D. White, C. Mullighan, C. Willman, J. Starý, J. Trka, J. Zuna (2015)
Characterization of leukemias with ETV6-ABL1 fusionHaematologica, 101
M. Jawhar, J. Schwaab, S. Schnittger, M. Meggendorfer, K. Sotlar, H. Horny, G. Metzgeroth, Sebastian Kluger, N. Naumann, C. Haferlach, T. Haferlach, P. Valent, W. Hofmann, A. Fabarius, N. Cross, A. Reiter (2015)
Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic MastocytosisBlood, 126
Jenna Podjasek, J. Butterfield (2013)
Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature.Leukemia research, 37 4
Dongyou Liu (2017)
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement
J. Chen, Yanli Hou, K. Roskin, D. Arber, C. Bangs, L. Baughn, A. Cherry, M. Ewalt, A. Fire, L. Frésard, H. Kearney, S. Montgomery, R. Ohgami, Kathryn Pearce, B. Pitel, J. Merker, J. Gotlib (2021)
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.Blood advances, 5 17
G. Tang, W. Tam, N. Short, P. Bose, David Wu, Stephanie Hurwitz, A. Bagg, H. Rogers, E. Hsi, Andrés Quesada, Wei Wang, R. Miranda, C. Bueso-Ramos, L. Medeiros, V. Nardi, R. Hasserjian, D. Arber, A. Orazi, K. Foucar, Sa Wang (2021)
Myeloid/lymphoid neoplasms with FLT3 rearrangementModern Pathology, 34
Z. Hu, Wei Wang, B. Thakral, Zhining Chen, Z. Estrov, C. Bueso-Ramos, S. Verstovsek, L. Medeiros, Sa Wang (2020)
Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institutionCytometry Part B: Clinical Cytometry, 100
P. Valent, C. Akin, D. Metcalfe (2017)
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Blood, 129 11
P. Valent, K. Sotlar, W. Sperr, A. Reiter, M. Arock, H. Horny (2015)
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features.Leukemia research, 39 1
N. Cross, Yvette Hoade, W. Tapper, G. Carreño-Tarragona, T. Fanelli, M. Jawhar, N. Naumann, Iwo Pieniak, Johannes Lübke, Sahra Ali, K. Bhuller, S. Burgstaller, C. Cargo, J. Cavenagh, A. Duncombe, E. Das‐Gupta, P. Evans, P. Forsyth, P. George, C. Grimley, F. Jack, L. Munro, V. Mehra, K. Patel, A. Rismani, G. Sciuccati, Rowena Thomas-Dewing, P. Thornton, A. Virchis, Simon Watt, L. Wallis, A. Whiteway, Kris Zegocki, B. Bain, A. Reiter, A. Chase (2018)
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophiliaLeukemia, 33
K. Hartmann, L. Escribano, C. Grattan, K. Brockow, M. Carter, I. Alvarez-Twose, A. Matito, S. Broesby‐Olsen, F. Siebenhaar, M. Lange, M. Niedoszytko, M. Castells, J. Elberink, P. Bonadonna, R. Zanotti, J. Hornick, A. Torrelo, J. Grabbe, A. Rabenhorst, B. Nedoszytko, J. Butterfield, J. Gotlib, A. Reiter, D. Radia, O. Hermine, K. Sotlar, T. George, T. Kristensen, H. Kluin-Nelemans, S. Yavuz, H. Hägglund, W. Sperr, L. Schwartz, M. Triggiani, M. Maurer, G. Nilsson, H. Horny, M. Arock, A. Órfão, D. Metcalfe, C. Akin, P. Valent (2016)
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.The Journal of allergy and clinical immunology, 137 1
J. Gotlib, H. Kluin-Nelemans, T. George, C. Akin, K. Sotlar, O. Hermine, F. Awan, E. Hexner, M. Mauro, D. Sternberg, M. Villeneuve, A. Labed, E. Stanek, K. Hartmann, H. Horny, P. Valent, A. Reiter (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.The New England journal of medicine, 374 26
A. Pardanani, M. Elliott, Terra Reeder, chin-Yang Li, E. Baxter, N. Cross, A. Tefferi (2003)
Imatinib for systemic mast-cell diseaseThe Lancet, 362
R. Zanotti, M. Bonifacio, G. Lucchini, W. Sperr, L. Scaffidi, B. Anrooij, H. Elberink, J. Rossignol, O. Hermine, A. Górska, M. Lange, E. Hadzijusufovic, C. Miething, S. Müller, C. Perkins, William Shomali, C. Elena, A. Illerhaus, M. Jawhar, R. Parente, F. Caroppo, O. Solomianyi, A. Zink, M. Mattsson, A. Yavuz, J. Panse, J. Várkonyi, M. Doubek, V. Sabato, C. Breynaert, V. Vučinić, T. Schug, H. Hägglund, Friederike Wortmann, K. Brockow, I. Angelova-Fischer, A. Fortina, M. Triggiani, A. Reiter, K. Hartmann, L. Malcovati, J. Gotlib, K. Shoumariyeh, M. Niedoszytko, M. Arock, H. Kluin-Nelemans, P. Bonadonna, P. Valent (2021)
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosisLeukemia, 36
A. Reiter, J. Gotlib (2017)
Myeloid neoplasms with eosinophilia.Blood, 129 6
M. Jawhar, J. Schwaab, Susanne Schnittger, M. Meggendorfer, Markus Pfirrmann, Karl Sotlar, Hans-Peter Horny, G. Metzgeroth, Sebastian Kluger, N. Naumann, C. Haferlach, T. Haferlach, P. Valent, W. Hofmann, A. Fabarius, N. Cross, N. Cross, A. Reiter (2016)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosisLeukemia, 30
A. Pardanani, Stephanie Brockman, S. Paternoster, H. Flynn, R. Ketterling, T. Lasho, C. Ho, chin-Yang Li, G. Dewald, A. Tefferi (2004)
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.Blood, 104 10
K. Umino, Shin-ichiro Fujiwara, T. Ikeda, Y. Toda, Shoko Ito, Kiyomi Mashima, D. Minakata, H. Nakano, R. Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, M. Ashizawa, Kaoru Hatano, Kazuya Sato, I. Oh, K. Ohmine, K. Muroi, Y. Kanda (2018)
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangementHematology, 23
Sanjeev Gupta, N. Jain, G. Tang, A. Futreal, Sa Wang, J. Khoury, Richard Yang, Hong Fang, K. Patel, R. Luthra, M. Routbort, B. Barkoh, Wei Chen, X. Mao, Jianhua Zhang, L. Medeiros, C. Bueso-Ramos, S. Loghavi (2020)
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications.Journal of the National Comprehensive Cancer Network : JNCCN, 18 10
Christina Duckworth, Linsheng Zhang, Shiyong Li (2014)
Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.International journal of clinical and experimental pathology, 7 2
Sa Wang, L. Hutchinson, G. Tang, Su Chen, P. Miron, Y. Huh, Dan Jones, C. Bueso-Ramos, S. Verstovsek, L. Medeiros, R. Miranda (2013)
Systemic mastocytosis with associated clonal hematological non‐mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD componentsAmerican Journal of Hematology, 88
H. Kaplan, R. Jin, C. Bifulco, J. Scanlan, D. Corwin (2022)
PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical LiteratureThe Oncologist, 27
H. Vu, Phan Xinh, M. Masuda, T. Motoji, A. Toyoda, Y. Sakaki, K. Tokunaga, Yuko Sato (2006)
FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocationLeukemia, 20
P. Strati, G. Tang, D. Duose, S. Mallampati, R. Luthra, K. Patel, M. Hussaini, A. Mirza, R. Komrokji, S. Oh, J. Mascarenhas, V. Najfeld, V. Subbiah, H. Kantarjian, G. Garcia-Manero, S. Verstovsek, Naval Daver (2018)
Myeloid/lymphoid neoplasms with FGFR1 rearrangementLeukemia & Lymphoma, 59
A. Tzankov, K. Reichard, R. Hasserjian, D. Arber, A. Orazi, Sa Wang (2022)
Updates on eosinophilic disordersVirchows Archiv, 482
J. Hernández-Boluda, Arturo Pereira, N. Zinger, L. Gras, R. Martino, E. Nikolousis, J. Finke, A. Chinea, A. Rambaldi, M. Robin, R. Saccardi, A. Natale, J. Snowden, P. Tsirigotis, C. Vallejo, G. Wulf, B. Xicoy, D. Russo, J. Maertens, É. Daguindau, S. Lenhoff, P. Hayden, T. Czerw, D. Mclornan, I. Yakoub-Agha (2022)
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTBone Marrow Transplantation, 57
T. Ernst, J. Score, M. Deininger, Claire Hidalgo-Curtis, P. Lackie, W. Ershler, J. Goldman, N. Cross, F. Grand (2011)
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemiaBritish Journal of Haematology, 153
Melissa Cessna, P. Paulraj, Benjamin Hilton, K. Sadre-Bazzaz, P. Szankasi, Alice Cluff, Jay Patel, D. Hoda, R. Toydemir (2019)
Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation.Cancer genetics, 238
J. Gotlib (2017)
Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.Hematology/oncology clinics of North America, 31 4
J. Gotlib (2022)
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.Hematology. American Society of Hematology. Education Program, 2022 1
G. Requena, J. Bosch, P. Akuthota, A. Kovalszki, J. Steinfeld, N. Kwon, M. Dyke (2022)
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.The journal of allergy and clinical immunology. In practice
Sa Wang, W. Tam, Albert Tsai, D. Arber, R. Hasserjian, J. Geyer, T. George, David Czuchlewski, K. Foucar, H. Rogers, E. Hsi, B. Rea, A. Bagg, P. Cin, Chong Zhao, T. Kelley, S. Verstovsek, C. Bueso-Ramos, A. Orazi (2016)
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specifiedModern Pathology, 29
T. Carll, A. Patel, B. Derman, E. Hyjek, Angela Lager, P. Wanjari, J. Segal, O. Odenike, S. Fidai, D. Arber (2020)
Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement.Blood advances, 4 19
Asuman Demiroglu, E. Steer, C. Heath, K. Taylor, M. Bentley, S. Allen, P. Koduru, J. Brody, G. Hawson, R. Rodwell, Marylou Doody, F. Carnicero, A. Reiter, J. Goldman, J. Melo, Nicholas Cross (2001)
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.Blood, 98 13
P. Ogbogu, B. Bochner, J. Butterfield, G. Gleich, J. Huss‐Marp, J. Kahn, K. Leiferman, T. Nutman, F. Pfab, J. Ring, M. Rothenberg, F. Roufosse, Marie-Helene Sajous, J. Sheikh, D. Simon, H. Simon, M. Stein, A. Wardlaw, P. Weller, A. Klion (2009)
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.The Journal of allergy and clinical immunology, 124 6
L. Escribano, I. Alvarez-Twose, L. Sánchez-Muñoz, A. García-Montero, R. Núñez, J. Almeida, M. Jara-Acevedo, Cristina Teodosio, M. García‐Cosío, C. Bellas, A. Órfão (2009)
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.The Journal of allergy and clinical immunology, 124 3
H. Kluin-Nelemans, M. Jawhar, A. Reiter, B. Anrooij, J. Gotlib, Karin, Hartmann, A. Illerhaus, H. Elberink, A. Górska, M. Niedoszytko, M. Lange, L. Scaffidi, R. Zanotti, P. Bonadonna, C. Perkins, C. Elena, Luca, Malcovati, K. Shoumariyeh, N. Bubnoff, S. Müller, M. Triggiani, Roberta, Parente, J. Schwaab, M. Kundi, A. Fortina, F. Caroppo, K. Brockow, A. Zink, D. Fuchs, I. Angelova-Fischer, A. Yavuz, M. Doubek, Mattias, Mattsson, H. Hagglund, J. Panse, Anne Simonowski, V. Sabato, T. Schug, M. Jentzsch, C. Breynaert, J. Várkonyi, Vanessa Kennedy, O. Hermine, J. Rossignol, Michel, Arock, P. Valent, W. Sperr (2021)
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosisTheranostics, 11
Ana Henriques, J. Muñoz-González, L. Sánchez-Muñoz, A. Matito, Lidia Torres-Rivera, M. Jara-Acevedo, C. Caldas, A. Mayado, A. Pérez-Pons, A. García-Montero, I. Alvarez-Twose, A. Órfão (2021)
Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis.Blood
B. Spitzer, F. Cruz, Glorymar Sanchez, Yanming Zhang, Wenbin Xiao, R. Benayed, A. Markova, M. Rodríguez-Sánchez, N. Bouvier, M. Roshal, A. Kung, N. Shukla (2021)
ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.Blood advances, 5 7
I. Alvarez-Twose, R. Zanotti, D. González-de-Olano, P. Bonadonna, A. Vega, A. Matito, L. Sánchez-Muñoz, J. Morgado, O. Perbellini, A. García-Montero, G. Matteis, Cristina Teodosio, M. Rossini, M. Jara-Acevedo, D. Schena, A. Mayado, A. Zamó, M. Mollejo, Paula Sánchez-López, N. Cabañes, A. Órfão, L. Escribano (2014)
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.The Journal of allergy and clinical immunology, 133 2
D. Steensma, R. Bejar, S. Jaiswal, R. Lindsley, M. Sekeres, R. Hasserjian, B. Ebert (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.Blood, 126 1
Max Jan, Daniel Grinshpun, J. Villalba, P. Cin, D. Sykes, A. Iafrate, B. Ebert, G. Hobbs, V. Nardi (2020)
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia.Blood advances, 4 3
A. Chung, Yanli Hou, R. Ohgami, Ann Gehr, D. Fisk, K. Roskin, Xu Li, Linda Gojenola, C. Bangs, D. Arber, A. Fire, A. Cherry, J. Zehnder, J. Gotlib, J. Merker (2017)
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.Cancer genetics, 216-217
Polina Pyatilova, C. Akin, I. Alvarez-Twose, M. Arock, P. Bonadonna, K. Brockow, J. Butterfield, S. Broesby‐Olsen, M. Carter, M. Castells, T. George, J. Gotlib, Georg Greiner, T. Gülen, K. Hartmann, O. Hermine, H. Horny, Mohamed Jawhar, M. Lange, J. Lyons, M. Maurer, D. Metcalfe, B. Nedoszytko, M. Niedoszytko, A. Órfão, A. Reiter, J. Schwaab, K. Sotlar, W. Sperr, M. Triggiani, P. Valent, F. Siebenhaar (2022)
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis proposed by the ECNM-AIM Consortium.The journal of allergy and clinical immunology. In practice
C. Cargo, N. Rowbotham, P. Evans, S. Barrans, D. Bowen, S. Crouch, A. Jack (2015)
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.Blood, 126 21
M. Munthe-Kaas, R. Forthun, A. Brendehaug, A. Eek, Trude Høysæter, L. Osnes, T. Prescott, S. Spetalen, R. Hovland (2020)
Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion.Journal of Pediatric Hematology/Oncology
G. Tang, John Philip, O. Weinberg, W. Tam, S. Sadigh, Jonathan Lake, Elizabeth Margolskee, H. Rogers, R. Miranda, Carlos C, E. Hsi, A. Orazi, R. Hasserjian, D. Arber, A. Bagg, Sa Wang (2018)
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter studyModern Pathology, 32
Guilin Tang, L. Medeiros, Sa Wang (2018)
How I investigate Clonal cytogenetic abnormalities of undetermined significanceInternational Journal of Laboratory Hematology, 40
Junshuai Xue, Jianjun Jiang, Yang Liu (2022)
The Neutrophil/Lymphocyte Ratio is an Independent Predictor of All-Cause Mortality in Patients with Idiopathic Hypereosinophilic SyndromeJournal of Inflammation Research, 15
Hannah Levavi, J. Tripodi, B. Marcellino, J. Mascarenhas, A. Jones, N. Cross, Diana Gruenstein, V. Najfeld (2019)
A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the LiteratureActa Haematologica, 142
F. Vega, L. Medeiros, C. Bueso-Ramos, Patricia Bermúdez, R. Miranda (2015)
Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.American journal of clinical pathology, 144 3
P. Valent, A. Klion, H. Horny, F. Roufosse, J. Gotlib, P. Weller, A. Hellmann, G. Metzgeroth, K. Leiferman, M. Arock, J. Butterfield, W. Sperr, K. Sotlar, P. Vandenberghe, T. Haferlach, H. Simon, A. Reiter, G. Gleich (2012)
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.The Journal of allergy and clinical immunology, 130 3
tyrosine kinase gene fusion including BCR::ABL1 , ETV6::ABL1 , PDGFRA , PDGFRB , FGFR1 , JAK2 , FLT3 fusions not meeting any other diagnostic criteria for AML, CMML, SM
S. Mueller, P. Cin, L. Le, D. Dias-Santagata, J. Lennerz, A. Iafrate, Hetal Marble, A. Brunner, M. Weinstock, M. Luskin, D. DeAngelo, R. Stone, V. Nardi (2021)
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivityBlood Advances, 6
Alexander Chao, Julia Meyer, Alex Lee, A. Hecht, Theodore Tarver, J. Ziffle, Ashley Koegel, C. Golden, B. Braun, E. Sweet-Cordero, Catherine Smith, Christopher Dvorak, M. Loh, Elliot Stieglitz (2019)
Fusion driven JMML: a novel CCDC88C–FLT3 fusion responsive to sorafenib identified by RNA sequencingLeukemia, 34
F. Grand, S. Iqbal, Lingyan Zhang, N. Russell, A. Chase, N. Cross (2007)
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.Experimental hematology, 35 11
D. Arber, A. Orazi, R. Hasserjian, M. Borowitz, K. Calvo, H. Kvasnicka, Sa Wang, A. Bagg, T. Barbui, S. Branford, C. Bueso-Ramos, J. Cortes, P. Cin, C. Dinardo, H. Dombret, E. Duncavage, B. Ebert, E. Estey, F. Facchetti, K. Foucar, N. Gangat, U. Gianelli, L. Godley, N. Goekbuget, J. Gotlib, E. Hellström-Lindberg, G. Hobbs, R. Hoffman, E. Jabbour, J. Kiladjian, R. Larson, M. Beau, M. Loh, B. Löwenberg, E. Macintyre, L. Malcovati, C. Mullighan, C. Niemeyer, O. Odenike, S. Ogawa, A. Órfão, E. Papaemmanuil, F. Passamonti, K. Porkka, C. Pui, J. Radich, A. Reiter, M. Rozman, M. Rudelius, M. Savona, C. Schiffer, Annette Schmitt-Graeff, A. Shimamura, J. Sierra, W. Stock, R. Stone, M. Tallman, J. Thiele, H. Tien, A. Tzankov, A. Vannucchi, P. Vyas, A. Wei, O. Weinberg, A. Wierzbowska, M. Cazzola, H. Döhner, A. Tefferi (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.Blood
Sarah Cohen, Stine Skovbo, H. Vestergaard, T. Kristensen, M. Møller, C. Bindslev‐Jensen, J. Fryzek, S. Broesby‐Olsen (2014)
Epidemiology of systemic mastocytosis in DenmarkBritish Journal of Haematology, 166
C. Walz, P. Erben, Michael Ritter, A. Bloor, G. Metzgeroth, N. Telford, C. Haferlach, T. Haferlach, S. Gesk, J. Score, W. Hofmann, A. Hochhaus, N. Cross, A. Reiter (2011)
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.Blood, 118 8
Z. Hu, P. Boddu, S. Loghavi, R. Miranda, Maitrayee Goswami, L. Medeiros, W. Tam, A. Orazi, S. Verstovsek, Sa Wang (2018)
A multimodality work‐up of patients with HypereosinophiliaAmerican Journal of Hematology, 93
L. Pieri, P. Bonadonna, C. Elena, C. Papayannidis, F. Grifoni, M. Rondoni, S. Girlanda, M. Mauro, D. Magliacane, E. Elli, M. Iorno, F. Almerigogna, F. Scarfì, R. Salerno, T. Fanelli, F. Gesullo, Giuditta Fattori, M. Bonifacio, O. Perbellini, A. Artuso, S. Soverini, C. Benedittis, S. Muratori, V. Pravettoni, Vittoria Cova, G. Cortellini, F. Ciceri, A. Cortelezzi, G. Martinelli, M. Triggiani, S. Merante, A. Vannucchi, R. Zanotti (2016)
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patientsAmerican Journal of Hematology, 91
Robin Jones, C. Serrano, M. Mehren, S. George, M. Heinrich, Yoon-Koo Kang, P. Schöffski, P. Cassier, O. Mir, S. Chawla, F. Eskens, P. Rutkowski, W. Tap, T. Zhou, M. Roche, S. Bauer (2021)
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialEuropean journal of cancer (Oxford, England : 1990), 145
M. Jawhar, J. Schwaab, N. Naumann, H. Horny, K. Sotlar, T. Haferlach, G. Metzgeroth, A. Fabarius, P. Valent, W. Hofmann, N. Cross, M. Meggendorfer, A. Reiter (2017)
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.Blood, 130 2
J. Trizuljak, W. Sperr, L. Nekvindová, H. Elberink, K. Gleixner, A. Górska, M. Lange, K. Hartmann, A. Illerhaus, M. Bonifacio, C. Perkins, C. Elena, L. Malcovati, A. Fortina, K. Shoumariyeh, M. Jawhar, R. Zanotti, P. Bonadonna, F. Caroppo, A. Zink, M. Triggiani, R. Parente, N. Bubnoff, Akif Yavuz, H. Hägglund, M. Mattsson, J. Panse, N. Jäkel, Alex Kilbertus, O. Hermine, M. Arock, D. Fuchs, V. Sabato, K. Brockow, A. Bretterklieber, M. Niedoszytko, B. Anrooij, A. Reiter, J. Gotlib, H. Kluin-Nelemans, J. Mayer, M. Doubek, P. Valent (2020)
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classificationAllergy, 75
A. García-Montero, M. Jara-Acevedo, Cristina Teodosio, M. Sánchez, R. Núñez, A. Prados, I. Aldanondo, Laura Sanchez, M. Domínguez, L. Botana, F. Sánchez-Jiménez, K. Sotlar, J. Almeida, L. Escribano, A. Órfão (2006)
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.Blood, 108 7
K. Kelemen, L. Saft, F. Craig, A. Orazi, M. Nakashima, G. Wertheim, T. George, H. Horny, R. King, L. Quintanilla‐Martinez, Sa Wang, L. Rimsza, K. Reichard (2020)
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.American journal of clinical pathology
F. Kuang, Fanny Legrand, M. Makiya, JeanAnne Ware, L. Wetzler, Thomas Brown, Tamika Magee, Brent Piligian, Pryscilla Yoon, Jamie Ellis, Xiaoping Sun, Sandhya Panch, Astin Powers, H. Alao, Sheila Kumar, Martha Quezado, Li Yan, Nancy Lee, Roland Kolbeck, Paul Newbold, Mitchell Goldman, Michael Fay, P. Khoury, Irina Maric, A. Klion (2019)
Benralizumab for PDGFRA‐Negative Hypereosinophilic SyndromeThe New England Journal of Medicine, 380
E. Troadec, S. Dobbelstein, P. Bertrand, N. Faumont, F. Trimoreau, M. Touati, J. Chauzeix, B. Petit, D. Bordessoule, J. Feuillard, C. Bastard, N. Gachard (2016)
A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?Leukemia, 31
S. Cherian, Vivian McCullouch, Valerie Miller, Katy Dougherty, J. Fromm, B. Wood (2016)
Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosisCytometry Part B: Clinical Cytometry, 90
I. Sadovnik, E. Lierman, B. Peter, H. Herrmann, Verena Suppan, G. Stefanzl, O. Haas, T. Lion, W. Pickl, J. Cools, P. Vandenberghe, P. Valent (2014)
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.Experimental hematology, 42 4
R. Leguit, Sa Wang, T. George, A. Tzankov, A. Orazi (2022)
The international consensus classification of mastocytosis and related entitiesVirchows Archiv, 482
R. Leguit, K. Hebeda, M. Kremer, J. Walt, U. Gianelli, A. Tzankov, A. Orazi (2019)
The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature ReviewPathobiology, 87
H. Fang, R. Ketterling, C. Hanson, A. Pardanani, Paul Kurtin, Dong Chen, P. Greipp, M. Howard, R. King, D. Dyke, K. Reichard (2018)
A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional ExperienceAmerican Journal of Clinical Pathology, 150
Ximena Montenegro-Garreaud, Ximena Montenegro-Garreaud, R. Miranda, Alexandra Reynolds, G. Tang, Sa Wang, M. Yabe, M. Yabe, Wei Wang, Lianghua Fang, C. Bueso-Ramos, P. Lin, L. Medeiros, Xinyan Lu (2017)
Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.Human pathology, 65
T. Kristensen, H. Vestergaard, M. Møller (2011)
Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.The Journal of molecular diagnostics : JMD, 13 2
K. Sotlar, Sema Colak, Anja Bache, S. Berezowska, M. Krokowski, B. Bültmann, P. Valent, H. Horny (2010)
Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD)The Journal of Pathology, 220
M. Jawhar, J. Schwaab, S. Schnittger, Karl Sotlar, H. Horny, G. Metzgeroth, N. Müller, S. Schneider, N. Naumann, C. Walz, T. Haferlach, P. Valent, W. Hofmann, Nicholas Cross, Nicholas Cross, A. Fabarius, A. Reiter (2015)
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventLeukemia, 29
Ken-Hong Lim, A. Pardanani, J. Butterfield, chin-Yang Li, A. Tefferi (2009)
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosineAmerican Journal of Hematology, 84
A. Pardanani, Sahrish Shah, F. Mannelli, Y. Elala, P. Guglielmelli, T. Lasho, M. Patnaik, N. Gangat, R. Ketterling, K. Reichard, C. Hanson, A. Vannucchi, A. Tefferi (2018)
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.Blood advances, 2 21
J. Schwaab, S. Schnittger, K. Sotlar, C. Walz, A. Fabarius, M. Pfirrmann, A. Kohlmann, V. Grossmann, M. Meggendorfer, H. Horny, P. Valent, M. Jawhar, M. Teichmann, G. Metzgeroth, P. Erben, T. Ernst, A. Hochhaus, T. Haferlach, W. Hofmann, N. Cross, A. Reiter (2013)
Comprehensive mutational profiling in advanced systemic mastocytosis.Blood, 122 14
Geisilene Silva, E. Tournier, L. Sarian, C. Bulai-Livideanu, G. Delsol, L. Lamant, J. Vassallo, P. Brousset, C. Laurent (2018)
Prevalence of CD30 immunostaining in neoplastic mast cellsMedicine, 97
W. Sperr, M. Kundi, I. Alvarez-Twose, B. Anrooij, J. Elberink, A. Górska, M. Niedoszytko, K. Gleixner, E. Hadzijusufovic, R. Zanotti, P. Bonadonna, M. Bonifacio, C. Perkins, A. Illerhaus, C. Elena, S. Merante, K. Shoumariyeh, N. Bubnoff, R. Parente, M. Jawhar, A. Fortina, F. Caroppo, K. Brockow, A. Zink, D. Fuchs, Alex Kilbertus, A. Yavuz, M. Doubek, H. Hägglund, J. Panse, V. Sabato, A. Bretterklieber, D. Niederwieser, C. Breynaert, K. Hartmann, M. Triggiani, B. Nedoszytko, A. Reiter, A. Órfão, O. Hermine, J. Gotlib, M. Arock, H. Kluin-Nelemans, P. Valent (2019)
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.The Lancet. Haematology
J Gotlib, J Schwaab, W Shomali (2022)
Proposed European competence network on mastocytosis‐American initiative in mast cell diseases (ECNM‐AIM) response criteria in advanced systemic mastocytosis, 10
J. Muñoz-González, I. Alvarez-Twose, M. Jara-Acevedo, R. Zanotti, C. Perkins, M. Jawhar, W. Sperr, K. Shoumariyeh, J. Schwaab, Georg Greiner, Ana Henriques, C. Caldas, C. Fernández-Giménez, L. Sánchez-Muñoz, A. Mayado, A. Pérez-Pons, A. Schmitt-Graeff, J. Duyster, I. Tanasi, Francesco Olivieri, E. Mora-Casterá, I. Luna, L. Senent, M. Bañas, Amanda Nuñez-García, M. Jurado-Chacón, G. Martín-Sánchez, E. Colado, B. Xicoy, G. Gener-Ricos, J. Gotlib, P. Bonadonna, A. Reiter, P. Valent, A. García-Montero, A. Órfão (2021)
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.The Lancet. Haematology
Haipeng Shao, Wei Wang, Jinming Song, G. Tang, Xiaohui Zhang, Zhenya Tang, J. Srivastava, B. Shah, L. Medeiros, Ling Zhang (2020)
Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.Leukemia research, 99
S. Georgin-lavialle, L. Lhermitte, P. Dubreuil, M. Chandesris, O. Hermine, G. Damaj (2013)
Mast cell leukemia.Blood, 121 8
Based on new data and increased understanding of disease molecular genetics, the international consensus classification (ICC) has made several changes in the diagnosis and classification of eosinophilic disorders and systemic mastocytosis. Myeloid/lymphoid neoplasms with eosinophilia (M/LN‐eo) and gene rearrangements have been renamed as M/LN‐eo with tyrosine kinase gene fusions (M/LN‐eo‐TK). The category has been expanded to include ETV6::ABL1 and FLT3 fusions, and to accept PCM1::JAK2 and its genetic variants as formal members. The overlaps and differences between M/LN‐eo‐TK and BCR::ABL1‐like B‐lymphoblastic leukemia (ALL)/de novo T‐ALL sharing the same genetic lesions are addressed. Besides genetics, ICC for the first time has introduced bone marrow morphologic criteria in distinguishing idiopathic hypereosinophilia/hypereosinophilic syndrome from chronic eosinophilic leukemia, not otherwise specified. The major diagnostic criteria for systemic mastocytosis (SM) in the ICC remain largely based on morphology, but several minor modifications/refinements have been made in criteria related to diagnosis, subclassification, and assessment of disease burden (B‐ and C‐findings). This review is to focus on the ICC updates related to these disease entities, illustrated through changes related to morphology, molecular genetics, clinical features, prognosis, and treatment. Two practical algorithms are provided in navigating through the diagnosis and classification systems of hypereosinophilia and SM.
American Journal of Hematology – Wiley
Published: Aug 1, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.